Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life

Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life

Abstract In the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, a...

Full description

Bibliographic Details
Main Authors: Nicolas Nagot, Mandisa Singata-Madliki, Amandine Cournil, Joyce Nalugya, Souleymane Tassembedo, Catherine Quillet, Melany W. Tonga, James Tumwine, Nicolas Meda, Chipepo Kankasa, Mwiya Mwiya, Paul Bangirana, Marianne Peries, Joanne Batting, Ingunn M. S. Engebretsen, Thorkild Tylleskär, Philippe Vande Perre, Grace Ndeezi, Jean-Pierre Molès
Format: Article
Language:English
Published: Nature Portfolio 2021-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-82762-8

Internet

https://doi.org/10.1038/s41598-021-82762-8

Similar Items